## JB Chemicals & Pharmaceuticals Limited (JBCHEPHARM) Investment Report - December 20, 2024

**1. Company Overview:**

JB Chemicals & Pharmaceuticals Limited (JBCHEPHARM) is a pharmaceutical company listed on the NSE (National Stock Exchange of India) since April 29, 2003.  It operates within the Pharmaceuticals & Biotechnology sector, specifically focusing on pharmaceuticals.  The company's exact market positioning within the sector requires further research beyond the provided data, but its presence on the NSE suggests a significant market capitalization and established presence.

**2. Market Data Analysis:**

| Metric                     | Value          | Notes                                                              |
|-----------------------------|-----------------|----------------------------------------------------------------------|
| Current Price               | ₹1,871.50       |  Down ₹41.75 (-2.18%) from the previous close.                       |
| Percentage Change (PChange) | -2.18%          | Negative daily performance.                                          |
| Pre-Open Activity          | ₹1,916.50       |  Higher than the previous close, suggesting potential upward pressure.|
| Week High                   | ₹2,030          | Achieved on August 16, 2024.                                      |
| Week Low                    | ₹1,435          | Achieved on December 21, 2023.  Significant weekly volatility.      |
| VWAP                        | ₹1,894.66       | Volume Weighted Average Price indicates average trading price.        |
| Sector PE                   | 48.69           | Price-to-Earnings ratio for the sector.                             |
| Symbol PE                   | 48.69           | Price-to-Earnings ratio for JBCHEPHARM.                             |
| Delivery Percentage         | 58.91%          | Relatively high delivery percentage suggests some institutional interest.|
| Market Depth                | Low              |  The provided order book data shows zero buy and sell quantities, indicating low market depth at the time of data capture. This needs further investigation with real-time data. |


**3. Financial Performance:**

The provided financial data shows the following trends (all figures in ₹):

| Quarter      | Revenue     | Expenditure | Profit After Tax | Diluted EPS |
|--------------|-------------|-------------|-----------------|-------------|
| Q2 FY25 (Sep) | 96,465      | 73,045      | 17,312           | 11.15        |
| Q1 FY25 (Jun) | 95,747      | 72,326      | 17,323           | 11.16        |
| Q4 FY24 (Mar) | 82,530      | 66,219      | 12,585           | 8.11         |
| Q3 FY24 (Dec) | 80,671      | 63,030      | 12,792           | 8.25         |
| Q2 FY24 (Sep) | 84,360      | 64,288      | 14,502           | 9.36         |


**Analysis:** Revenue shows a slight decline from Q2 FY24 to Q4 FY24, followed by an increase in Q1 and Q2 FY25. Profit after tax and diluted EPS follow a similar pattern, indicating some seasonality or cyclical factors.  Further analysis is needed to determine the underlying causes of these fluctuations.  The unaudited nature of some quarters necessitates caution.

**4. Corporate Actions and Announcements:**

* **Dividends:**  The company has a history of paying regular dividends, both interim and final, with recent payouts of ₹6.75 and ₹5.50 per share.
* **Stock Split:** A face value split occurred in September 2023, changing the face value from ₹2 to ₹1.
* **Announcements:** Recent announcements include updates on capital alteration, fund raising, ESOPs, and analyst meetings.  These announcements suggest ongoing corporate activity and potential future growth initiatives.  The specific content of these announcements requires further review.

**5. Shareholding Patterns:**

| Quarter      | Promoter & Promoter Group | Public | Shares held by Employee Trusts | Total |
|--------------|---------------------------|--------|-------------------------------|-------|
| 30-Sep-2023  | 53.86%                     | 46.14% | 0.00%                         | 100.00%|
| 31-Dec-2023  | 53.83%                     | 46.17% | 0.00%                         | 100.00%|
| 31-Mar-2024  | 53.78%                     | 46.22% | 0.00%                         | 100.00%|
| 30-Jun-2024  | 53.77%                     | 46.23% | 0.00%                         | 100.00%|
| 30-Sep-2024  | 53.74%                     | 46.26% | 0.00%                         | 100.00%|

Promoter holding has shown a slight downward trend over the past year, while public holding has correspondingly increased. This trend warrants further investigation to understand the reasons behind the change.

**6. Volatility and Risk Assessment:**

The stock exhibits significant volatility, as evidenced by the week high and low. The CM Annual Volatility of 34.2% further confirms this.  The low market depth adds to the risk profile, as large trades could significantly impact the price.  The risk-reward profile is currently skewed towards higher risk due to volatility and low liquidity.

**7. Advantages of Buying the Stock:**

* Consistent dividend payouts.
* Relatively high delivery percentage.
* Ongoing corporate actions suggesting growth initiatives.

**8. Disadvantages and Risks:**

* High volatility.
* Low market depth.
* Recent decline in revenue and profit (though showing signs of recovery).
* Unaudited financial data for some quarters.


**9. Investment Horizon Recommendations:**

* **Short-term (less than 3 months): Hold.** The current price is below the pre-open price, and the low market depth makes short-term trading risky.  Waiting for clearer market signals is advisable.

* **Medium-term (3 to 12 months): Hold.**  The medium-term outlook depends on the company's ability to sustain revenue growth and improve profitability.  Further analysis of the recent announcements and financial statements is needed.

* **Long-term (1 year and beyond): Hold/Consider Buy (with caution).**  The company's history of dividend payouts and consistent promoter holding (though slightly decreasing) suggests long-term potential. However, the volatility and low market depth remain significant concerns.  A long-term investment should only be considered after thorough due diligence and a deeper understanding of the company's future prospects.


**10. Stock and Analysis Scoring:**

**Stock Score (out of 10): 6.5**

* **Financial Health (3/5):**  Moderate financial performance with some recent decline but showing signs of recovery.
* **Market Performance (2/5):** High volatility and low market depth are significant drawbacks.
* **Volatility and Risk (1/5):** High volatility and low liquidity present substantial risk.
* **Corporate Actions and Governance (4/5):** Consistent dividend payouts and ongoing corporate actions are positive.
* **Shareholding Patterns (4/5):**  Slight decrease in promoter holding warrants monitoring.

**Analysis Score (out of 10): 8**

* **Completeness and Utilization of Data (4/5):** Most data points were used effectively.
* **Accuracy and Clarity of Analysis (4/5):** Analysis is clear and well-structured, but some aspects require further investigation.
* **Professional Formatting (5/5):** Report is well-formatted and easy to understand.


**11. Professional Recommendation Summary:**

Based on the analysis of the provided data, JBCHEPHARM is currently a **Hold** for short-term and medium-term investment strategies.  A **Hold/Consider Buy (with caution)** recommendation is given for the long term, contingent upon further due diligence and a more comprehensive understanding of the company's future prospects and the reasons behind the recent fluctuations in financial performance and shareholding patterns.  The high volatility and low market depth necessitate a cautious approach.  Real-time data and further research are crucial before making any investment decisions.
